{"disease":{"id":"nsclc-stage-iiia","name":"nsclc stage iiia"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03509779","title":"Pronostic and Predictive Value of EMT in Localized Lung Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"European Georges Pompidou Hospital","has_results":false},{"nct_id":"NCT07128199","title":"A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":360,"lead_sponsor_name":"Taiho Oncology, Inc.","has_results":false},{"nct_id":"NCT03736993","title":"Metabolomics Predict Therapy Response","phase":"NA","overall_status":"COMPLETED","enrollment_count":160,"lead_sponsor_name":"Hasselt University","has_results":false},{"nct_id":"NCT06856798","title":"Construction of a Prognostic and Prediction Model for Perioperative Immunotherapy in NSCLC: A Multi - Omics Perspective","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Ziming Li","has_results":false},{"nct_id":"NCT05157776","title":"A Phase III Trial of Neoadjuvant Sintilimab and Chemotherapy for NSCLC Harboring No Driver Mutations","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":72,"lead_sponsor_name":"Tongji University","has_results":false},{"nct_id":"NCT06780839","title":"Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":70,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT06614231","title":"Neoajuvant Tislelizumab Combined with Chemotherapy for Initially Unresectable Stage IIIA/N2 Non-small Cell Lung Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":48,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT07492342","title":"Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Jianxing He","has_results":false},{"nct_id":"NCT04865250","title":"Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"University Hospital Heidelberg","has_results":false}],"total":9},"guidelines":[],"source":"Drug Landscape verified database"}